Suppr超能文献

先前治疗对干细胞因子加非格司亭动员的CD34阳性祖细胞体外增殖潜力的影响。

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.

作者信息

Shapiro F, Yao T J, Moskowitz C, Reich L, Wuest D L, Heimfeld S, McNiece I K, Gabrilove J, Nimer S, Moore M A

机构信息

James Ewing Laboratory of Developmental Hematopoiesis, Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

出版信息

Clin Cancer Res. 1997 Sep;3(9):1571-8.

PMID:9815845
Abstract

The quantity of hematopoietic progenitors in an apheresis collection is defined by the number of CD34(+) cells or granulocyte macrophage colony-forming units present. These parameters are believed to give roughly equivalent information on graft quality. We here report that the in vitro proliferative potential of r-metHuSCF (stem cell factor) plus filgrastim (granulocyte colony-stimulating factor; r-metHuG-CSF) mobilized peripheral blood (PB) CD34(+) cells obtained from previously heavily treated non-Hodgkin's lymphoma patients inversely correlates with extent of prior therapy. CD34(+) cells were enriched using the CellPro Ceprate system and placed in liquid culture for 4 weeks in the presence of either r-metHuSCF, IL-3, IL-6, filgrastim (S36G), or S36G plus erythropoietin (S36GE) with a weekly exchange of media and cytokines with reestablishment of culture at the starting cell concentration (Delta assay) and enumeration of progenitors. Starting with 4 x 10(4) CD34(+) cells from apheresis samples from patients who had received <10 cycles of prior chemotherapy, progenitors were detectable in culture at 4 weeks 81% of the time as compared to 14% with CD34(+) cells from patients who had received >10 cycles and 5% for >10 cycles plus radiotherapy. The total number of progenitors generated over the duration of culture (area under the curve) was calculated using the trapezoidal rule as a novel measure of the proliferative potential of the enriched PB CD34(+) cell population. The median area under the curve of CD34(+) cells from patients receiving <10 cycles of prior chemotherapy was 7.4 and 5.7 (x10(5)) using S36G or S36GE, respectively, 1.8 and 1.9 if the patients received >10 cycles of prior chemotherapy, and 1.4 and 1.2 if the patients received >10 cycles of prior chemotherapy plus radiotherapy (P < 0.001). These data show that prior therapy impacts on the quality of PB CD34(+) cells as measured by their ability to generate committed progenitors over a number of weeks in liquid culture.

摘要

单采血液成分中造血祖细胞的数量由存在的CD34(+)细胞或粒细胞巨噬细胞集落形成单位的数量来定义。这些参数被认为能提供大致等效的关于移植物质量的信息。我们在此报告,从先前接受过大量治疗的非霍奇金淋巴瘤患者获得的r-甲硫氨酸人干细胞因子(r-metHuSCF)加非格司亭(粒细胞集落刺激因子;r-metHuG-CSF)动员的外周血(PB)CD34(+)细胞的体外增殖潜力与先前治疗的程度呈负相关。使用CellPro Ceprate系统富集CD34(+)细胞,并在r-metHuSCF、白细胞介素-3、白细胞介素-6、非格司亭(S36G)或S36G加促红细胞生成素(S36GE)存在的情况下进行4周的液体培养,每周更换培养基和细胞因子,并以起始细胞浓度重新建立培养(增量测定)并对祖细胞进行计数。从接受<10个周期先前化疗的患者的单采样本中获取4×10(4)个CD34(+)细胞开始,4周时在培养物中可检测到祖细胞的时间为81%,而接受>10个周期化疗的患者的CD34(+)细胞为14%,接受>10个周期化疗加放疗的患者为5%。使用梯形法则计算培养期间产生的祖细胞总数(曲线下面积),作为富集的PB CD34(+)细胞群体增殖潜力的一种新度量。接受<10个周期先前化疗的患者的CD34(+)细胞的曲线下面积中位数,使用S36G或S36GE时分别为7.4和5.7(×10(5)),接受>10个周期先前化疗的患者为1.8和1.9,接受>10个周期先前化疗加放疗的患者为1.4和1.2(P<0.001)。这些数据表明,先前治疗会影响PB CD34(+)细胞的质量,这通过它们在液体培养中数周内产生定向祖细胞的能力来衡量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验